Abstract:Background: Humanization of mouse monoclonal antibodies (mAbs) is crucial for reducing their immunogenicity in humans. However, humanized mAbs often lose their binding affinities. Therefore, an in silico humanization method that can prevent the loss of the binding affinity of mAbs is needed. Methods: We developed an in silico V(D)J recombination platform in which we used V(D)J human germline gene sequences to design five humanized candidates of anti-tumor necrosis factor (TNF)-α mAbs (C1-C5) by using different human germline templates. The candidates were subjected to molecular dynamics simulation. In addition, the structural similarities of their complementarity-determining regions (CDRs) to those of original mouse mAbs were estimated to derive the weighted interatomic root mean squared deviation (wRMSDi) value. Subsequently, the correlation of the derived wRMSDi value with the half maximal effective concentration (EC50) and the binding affinity (KD) of the humanized anti-TNF-α candidates was examined. To confirm whether our in silico estimation method can be used for other humanized mAbs, we tested our method using the anti-epidermal growth factor receptor (EGFR) a4.6.1, anti-glypican-3 (GPC3) YP9.1 and anti-α4β1 integrin HP1/2L mAbs. Results: The R2 value for the correlation between the wRMSDi and log(EC50) of the recombinant Remicade and those of the humanized anti-TNF-α candidates was 0.901, and the R2 value for the correlation between wRMSDi and log(KD) was 0.9921. The results indicated that our in silico V(D)J recombination platform could predict the binding affinity of humanized candidates and successfully identify the high-affinity humanized anti-TNF-α antibody (Ab) C1 with a binding affinity similar to that of the parental chimeric mAb (5.13 × 10-10). For the anti-EGFR a4.6.1, anti-GPC3 YP9.1, and anti-α4β1 integrin HP1/2L mAbs, the wRMSDi and log(EC50) exhibited strong correlations (R2 = 0.9908, 0.9999, and 0.8907, respectively). Conclusions: Our in silico V(D)J recombination platform can facilitate the development of humanized mAbs with low immunogenicity and high binding affinities. This platform can directly transform numerous mAbs with therapeutic potential to humanized or even human therapeutic Abs for clinical use.

De Novo Generation of Specific Human IgGs by in Vitro Immunization Using Autologous Proteins Containing Immunogenic P-Nitrophenylalanine.

Generation and Characterization of Four Novel Monoclonal Antibodies Against Human Programmed Death-1 Molecule.

Efficient Acquisition of Fully Human Antibody Genes Against Self-Proteins by Sorting Single B Cells Stimulated with Vaccines Based on Nitrated T Helper Cell Epitopes

Generation of IgE-specific Cytotoxic T Lymphocytes As a Novel Immunotherapeutic Approach for the Treatment of Allergic Asthma.

Rapid de novo generation of antigen specific human B cells with expression of Blimp‐1 and AID by in vitro immunization

Generation of Human Neutralizing Monoclonal Antibodies Against the 2009 Pandemic H1N1 Virus from Peripheral Blood Memory B Lymphocytes.

Overexpression, Effective Renaturation, And Bioactivity Of Novel Single-Chain Antibodies Against Tnf-Alpha

Overexpression, Effective Renaturation, and Bioactivity of Novel Single-Chain Antibodies Against TNF-α

Anti-Peptide Antibody Production Elicited by in Vitro Immunization of Human Peripheral Blood Mononuclear Cells

High throughput monoclonal antibody generation by immunizing multiple antigens

Affinity Maturation of Anti-Tnf-Alpha Scfv with Somatic Hypermutation in Non-B Cells

Generating Anti-TIGIT and CD155 Monoclonal Antibodies for Tumor Immunotherapy

Designing and constructing a phage display synthesized single domain antibodies library based on camel VHHs frame for screening and identifying humanized TNF-α-specific nanobody

Generation of Genetic Engineering Monoclonal Antibodies Against Prion Protein

Optimization of in Vitro Immunization Protocol to Produce Antigen Specific Human Monoclonal Antibody by Demonstrating the Role of IL-10

A Novel Approach to Development of Monoclonal Antibodies Using Native Antigen for Immunization and Recombinant Antigen for Screening.

A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies

A Rapid and Simple Approach to Preparation of Monoclonal Antibody Based on Dna Immunization

Immunoglobulin somatic hypermutation in a defined biochemical system recapitulates affinity maturation and permits antibody optimization

Generation and Characterization of Polyclonal Antibodies Against Mouse T-cell Immunoglobulin and Immunoreceptor Tyrosine-Based Inhibitory Domain by DNA-based Immunization.

Novel human single chain antibody design based on the functional epitope of TNF